(September 17, 2018, 1:59 PM EDT) -- WASHINGTON, D.C. — Merck Sharp & Dohme Corp. on Sept. 13 filed its opening brief asking the U.S. Supreme Court to find that the Food and Drug Administration considered and rejected a warning that the company’s osteoporosis drug Fosamax has a risk of femur fractures (Merck Sharp & Dohme Corp. v. Doris Albrecht, et al., No. 17-290, U.S. Sup.)....